Dipyridamole, an antiplatelet drug used to prevent thromboembolic events, was developed in the 1960s and approved for medical use in the 1970s. Its history is marked by its effectiveness in inhibiting platelet aggregation and reducing the risk of stroke when used alone or in combination with other antithrombotic agents. Dipyridamole is often used in combination therapy with aspirin for secondary stroke prevention and as part of certain cardiac stress testing protocols. Its development included extensive clinical evaluation, and it remains a valuable option in cardiovascular disease management, with monitoring required for patients at risk of bleeding or with severe cardiovascular conditions.
BRAND NAMES
Persantine – commonly used as an antiplatelet agent and in cardiac stress testing.
Aggrenox – a combination of dipyridamole and aspirin, primarily indicated for secondary stroke prevention.
Dipyridamole Intensol – an oral solution formulation used in some regions.
MECHANISM OF ACTION
The mechanism of action of Dipyridamole involves inhibition of platelet aggregation through multiple pathways. Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells, and erythrocytes, leading to increased extracellular adenosine levels. Elevated adenosine stimulates adenosine A2 receptors on platelets, which increases cyclic adenosine monophosphate (cAMP) and inhibits platelet activation and aggregation.
PHARMACOKINETICS
Absorption
The absorption of Dipyridamole occurs primarily through the gastrointestinal tract after oral administration. Dipyridamole is rapidly absorbed, but its bioavailability is relatively low (about 37–66%) due to first-pass hepatic metabolism. Peak plasma concentrations are typically reached within 1–2 hours after ingestion of immediate-release formulations.
Distribution
The volume of distribution (Vd) of Dipyridamole is approximately 0.5–0.7 L/kg, indicating moderate distribution into body tissues beyond the plasma. Dipyridamole is highly protein-bound (about 99%), primarily to albumin, which limits free drug availability but maintains a stable plasma concentration for antiplatelet activity.
Metabolism
The metabolism of Dipyridamole occurs primarily in the liver. Dipyridamole undergoes extensive hepatic metabolism, mainly through phase I oxidative pathways and phase II conjugation reactions, producing inactive metabolites.
Elimination
The elimination of Dipyridamole occurs primarily via hepatic metabolism, with the resulting inactive metabolites excreted mostly in the bile and, to a lesser extent, in the urine. The drug has a plasma elimination half-life of approximately 10–12 hours for immediate-release formulations.
PHARMACODYNAMICS
The pharmacodynamics of Dipyridamole are centered on its antiplatelet and vasodilatory effects. Dipyridamole inhibits the uptake of adenosine into platelets and endothelial cells, increasing extracellular adenosine levels, which in turn stimulates adenosine A2 receptors. This elevates cyclic AMP (cAMP) within platelets, inhibiting platelet activation and aggregation.
ADMINISTRATION
The administration of Dipyridamole is primarily oral, available in immediate-release tablets, extended-release tablets, and combination formulations with aspirin. Immediate-release tablets are typically taken four times daily, while extended-release or combination products, such as Aggrenox, are usually administered twice daily to improve adherence and maintain consistent plasma levels.
DOSAGE AND STRENGTH
The dosage and strength of Dipyridamole depend on the formulation and therapeutic indication. Immediate-release tablets are typically administered at 25–50 mg orally four times daily, while extended-release tablets are usually given at 200 mg orally twice daily to maintain consistent plasma levels and improve adherence. For combination therapy with aspirin, such as in Aggrenox, each capsule contains 200 mg dipyridamole and 25 mg aspirin, taken twice daily for secondary stroke prevention.
DRUG INTERACTIONS
The drug interactions of Dipyridamole are primarily related to its antiplatelet and vasodilatory effects. Concomitant use with other antithrombotic or anticoagulant agents such as warfarin, heparin, or other antiplatelet drugs may increase the risk of bleeding complications.
FOOD INTERACTIONS
The food interactions of Dipyridamole are generally minimal. Dipyridamole can be taken with or without food, although high-fat meals may slightly delay absorption of immediate-release formulations without significantly affecting overall bioavailability. Patients should avoid excessive alcohol, as it may enhance vasodilatory effects and increase the risk of headache or hypotension.
CONTRAINDICATIONS
The contraindications of Dipyridamole include known hypersensitivity to dipyridamole, aspirin (for combination formulations), or any component of the drug. It should not be used in patients with active bleeding disorders, such as peptic ulcer disease or intracranial hemorrhage, due to the increased risk of bleeding. Dipyridamole is also contraindicated in individuals with severe coronary artery disease or recent myocardial infarction, as its vasodilatory effects may trigger angina.
SIDE EFFECTS
Headache
Dizziness or lightheadedness
Nausea or gastrointestinal discomfort
Flushing
OVER DOSAGE
Overdosage of Dipyridamole can result in excessive vasodilation and enhanced antiplatelet effects, leading to clinical manifestations such as severe headache, dizziness, hypotension, flushing, nausea, vomiting, and tachycardia. In cases of combination therapy with aspirin (e.g., Aggrenox), there is also an increased risk of bleeding, including gastrointestinal or intracranial hemorrhage.
TOXICITY
Toxicity of Dipyridamole results from excessive vasodilation and enhanced antiplatelet activity, typically due to overdose or high-dose therapy. Clinical manifestations may include severe headache, dizziness, hypotension, flushing, palpitations, nausea, and vomiting. In combination formulations with aspirin, there is an increased risk of serious bleeding, such as gastrointestinal or intracranial hemorrhage.
